Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion

Status Completed

Clinical Trial Summary

This study will investigate the absorption, distribution, metabolism and excretion after giving 2000 mg 14C-SLV334 via a 1-hour infusion. The absolute bioavailability will also be determined.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Pharmacology, Clinical

Clinical Trial Details

NCT number	NCT01044524
Study type	Interventional
Source	Solvay Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	February 2010
Completion date	March 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00941057` - Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium	Phase 1
Completed	`NCT01707407` - A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects	Phase 1
Terminated	`NCT04320771` - Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight	Phase 1
Completed	`NCT00855660` - Effect of Riociguat on Bone Metabolism	Phase 1
Completed	`NCT03929861` - Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations	Phase 1
Completed	`NCT01489488` - Relative Bioavailability and Food Effect Study	Phase 1
Completed	`NCT02394093` - To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.	Phase 1
Terminated	`NCT04322253` - Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight	Phase 1